MORRISTOWN, N.J.--(BUSINESS WIRE)-- Durata Therapeutics (DRTX) today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences acted as the co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 18, 2012. Copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or via email, at firstname.lastname@example.org or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone 800-221-1037, or via email, at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.
Justin Jackson, firstname.lastname@example.org
Michelle Szwarcberg, email@example.com
Corey Fishman, (973) 993-4865
Chief Operating Officer and Chief Financial Officer